Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06315166 · ClinicalTrials.gov registry record · NA
Study on Using Radiofrequency to Treat Moderate to Severe Acne
A NA study of Moderate to Severe Acne Vulgaris, sponsored by Pollogen.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06315166: Active NA study of Moderate to Severe Acne Vulgaris, sponsored by Pollogen.
NCT06315166 is a NA study of Moderate to Severe Acne Vulgaris that is active but no longer recruiting, run by Pollogen. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06315166, a NA study of Moderate to Severe Acne Vulgaris, is active but no longer recruiting, sponsored by Pollogen.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation of the safety and efficacy of fractional radiofrequency for the treatment of moderate to severe acne vulgaris.
Primary Outcome
Improvement in acne vulgaris compared to baseline utilizing the Acne Grading Scoring System (AGSS).
Conditions Studied
Interventions
- DEVICE triLift/Legend Pro+ Fractional RF System
Study Locations (1)
Michigan
- Cosmedic Dermatology (CosmedicDerm) - Grosse Pointe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-05-23 |
| Est. Completion | 2027-12 |
| Phase | NA |
What the registry record for NCT06315166 still lists
NCT06315166 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Moderate to Severe Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which triLift/Legend Pro+ Fractional RF System is the first listed.
NCT06315166 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06315166 about?
NCT06315166 is a clinical study titled "Study on Using Radiofrequency to Treat Moderate to Severe Acne". Evaluation of the safety and efficacy of fractional radiofrequency for the treatment of moderate to severe acne vulgaris.
What is the current status of trial NCT06315166?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-05-23. Estimated completion is 2027-12.
What conditions does trial NCT06315166 study?
This clinical trial studies the following conditions: Moderate to Severe Acne Vulgaris.
What interventions are being tested in trial NCT06315166?
The interventions under investigation include: triLift/Legend Pro+ Fractional RF System (DEVICE).
Who is sponsoring clinical trial NCT06315166?
This trial is sponsored by Pollogen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06315166 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06315166's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI